Neuromuscular Center, Clinic of Neurology, Jena University Hospital

The Neuromuscular Center Jena provides primary and secondary care for patients with motor neurone diseases and neuromuscular diseases. We cover the full range of diagnostics; provide ICU treatment, feeding tube placement and NIV services, regular clinical visits, and coordination of support measures. Our clinical research projects focus on MND biomarker identification in primary patient material and neuroimaging in order to analyse causes and paths of ALS progression. Furthermore, our center is involved in several clinical studies.

Neuromuscular Center, Clinic of Neurology, Jena University Hospital
Foundation year



Prof. Dr. med. Matthias Schwab

Principal investigator

Dr. Annekathrin Rödiger and Dr. Robert Steinbach

Contact information

Am Klinikum 1
07747 Jena


Dr. Beatrice Stubendorff


+49 3641 9 323534

Website Visit the website


  1. Steinbach R, Gaur N, Roediger A, Mayer TE, Witte OW, Prell T, Grosskreutz J. Disease aggressiveness signatures of amyotrophic lateral sclerosis in white matter tracts revealed by the D50 disease progression model. Hum Brain Mapp. 2021 Feb 15;42(3):737-752. doi: 10.1002/hbm.25258. Epub 2020 Oct 26.
  2. Steinbach R, Prell T, Gaur N, Roediger A, Gaser C, Mayer TE, Witte OW, Grosskreutz J. Patterns of grey and white matter changes differ between bulbar and limb onset amyotrophic lateral sclerosis. Neuroimage Clin. 2021;30:102674. doi: 10.1016/j.nicl.2021.102674. Epub 2021 Apr 15.
  3. Steinbach R, Prell T, Gaur N, Stubendorff B, Roediger A, Ilse B, Witte OW, Grosskreutz J. Triage of Amyotrophic Lateral Sclerosis Patients during the COVID-19 Pandemic: An Application of the D50 Model. J Clin Med. 2020 Sep 5;9(9):2873. doi: 10.3390/jcm9092873.
  4. Gaur N, Huss E, Prell T, Steinbach R, Guerra J, Srivastava A, Witte OW, Grosskreutz J. Monocyte-Derived Macrophages Contribute to Chitinase Dysregulation in Amyotrophic Lateral Sclerosis: A Pilot Study. Front Neurol. 2021 May 14;12:629332. doi: 10.3389/fneur.2021.629332.
  5. Dreger M, Steinbach R, Gaur N, Metzner K, Stubendorff B, Witte OW, Grosskreutz J. Cerebrospinal Fluid Neurofilament Light Chain (NfL) Predicts Disease Aggressiveness in Amyotrophic Lateral Sclerosis: An Application of the D50 Disease Progression Model. Front Neurosci. 2021 Apr 6;15:651651. doi: 10.3389/fnins.2021.651651.

Restricted information

Serving population
Serving population


Patient resources
Population based register


Clinic based register


Geographically matched controls


Number of muscle samples


Number of skin samples



Type ALS Patients Controls Other
DNA Bank 200 150 100
Serum Bank 350 100 350
RNA Bank 125 35 10
Research activities
Clinical management research


Neuro epidemiology


Neuro physiology


Neuro imaging


Neuro psychology


Neuro pathology








Clinical Trials - Industry sponsored

Name Type Patients
Courage-ALS (Cytokinetics) A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis
MT-1186-A02 (Mitsubishi Tanabe Pharma Development America, Inc.) Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS
Phoenix (Amylyx Pharmaceuticals Inc.) Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment
MERIDIAN (Apellis Pharmaceuticals, Inc.) Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)

Clinical Trials - Investigator initiated

Name Type Patients
SMArtCARE (University of Freiburg) Follow-up observation and therapy evaluation in spinal muscular atrophy
NFL study (Charité Berlin) Research program on the biomarker neurofilament light chain in ALS
ID-ALS (Charité Berlin) Research program for the identification of genetic changes in ALS
TUDCA-ALS (Humanitas Mirasole S.p.A.) Safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis